在AML中,布苏尔方耐药性与线粒体拷贝数和脂质代谢的变化有关
Vid Mlakar1, Simona Jurković Mlakar2,3, Yvonne Gloor2
1CANSEARCH Research Platform for Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology, and Obstetrics, University of Geneva, Geneva, Switzerland. vid.mlakar@unige.ch.
Scientific reports
|February 23, 2026
概括
急性髓性白血病 (AML) 细胞中的布苏尔方耐药性与线粒体DNA复制数 (mtDNA-CN) 的增加有关. 这项研究揭示,布苏尔 (BU) 耐药性涉及mtDNA-CN和基因表达的变化,提供潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 布苏尔 (BU) 是一种破坏DNA的物质,也是反应性氧物种 (ROS) 的来源.
- 线粒体DNA拷贝数 (mtDNA-CN) 和ROS水平影响对某些化疗药物的敏感性.
- 对BU和其他有关mtDNA-CN变化的药物耐药性的机制尚未完全理解.
研究的目的:
- 为了研究对busulfan (BU) 或cytarabine (Cyt) 的耐药性与急性髓性白血病 (AML) 细胞系中mtDNA-CN和基因表达的改变之间的关联.
- 探索潜在的分子目标,以克服BU抵抗.
主要方法:
- 通过连续的药物治疗,产生了抗BU (5TBU) 和联合抗BU/抗Cyt的AML细胞系.
- 使用RT-qPCR针对线粒体基因MTND1.1进行评估mtDNA-CN.
- 通过大量RNA测序分析了全球基因表达特征.
- 与细胞系中的mtDNA-CN相关的BU半最大抑制度 (BU-IC50).
主要成果:
- 在MOLM13细胞中获得的BU和Cyt耐药性通过增加IC50值得到证实.
- 抗BU细胞显示mtDNA-CN显著增加,而Cyt治疗没有改变mtDNA-CN.
- 转录组分析揭示了抗BU细胞中胆固醇和脂肪酸运输和合成途径的失调.
- 较高的BU-IC50值与AML衍生细胞和淋巴状细胞 (LCL) 中mtDNA-CN增加相关.
结论:
- 在AML细胞中获得的对busulfan的耐药性与mtDNA-CN的增加以及脂质代谢途径的显著改变有关.
- 这些发现表明mtDNA-CN和脂质代谢是BU耐药性的关键适应机制.
- 这项研究为BU抵抗机制提供了新的见解,突出了治疗干预的潜在目标.
相关概念视频
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
45
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
45
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Electron Transport Chain: Complex I and II
19.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.2K


